Company intelligence / Profile preview

CerbACT Asia

Ownership: Private
Development stage: Other

Overview

CerbACT Asia is a joint venture between Cerba Research and ACT Genomics providing advanced central laboratory and translational research services for immuno-oncology drug developers. The facility in Taipei offers cutting-edge flow cytometry, histopathology/IHC, PBMC isolation, and NGS-based genomics testing to support precision medicine in oncology clinical trials across the Asia-Pacific region. It does not develop its own therapeutics but enables biotech/pharma clients to accelerate their programs with deep biomarker expertise.

Modalities: Diagnostic testing (Flow cytometry)Diagnostic testing (Histopathology)Diagnostic testing (Immunohistochemistry)Diagnostic testing (NGS sequencing)
Industry: Contract Research Organization

Partnerships

ACT GenomicsCerba Research/Cerba HealthCare

Beyond the preview

Go deeper on CerbACT Asia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CerbACT Asia.

Explore the full profile